Siemens Healthineers: confirms annual targets
(CercleFinance.com) - Due to the gradual decline in the rapid antigen testing business, Q2 2023 comparable sales fell 2.
5% y-o-y to E5,346m.
Comparable sales growth was 11.2% in Q2 ended 31 March 2023, excluding COVID-19 rapid antigen tests.
Diagnostics segment sales declined 39.0% on a comparable basis, again due to the decline in the COVID-19 rapid antigen test business.
Adjusted EBIT fell by 30% to E681 million, resulting in a lower adjusted EBIT margin of 12.7%. Net profit slumped 81% to E108m. Adjusted basic EPS was lower than the same period last year, at E0.43. Excluding rapid antigen tests and transformation costs, adjusted basic EPS increased by 11%.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
5% y-o-y to E5,346m.
Comparable sales growth was 11.2% in Q2 ended 31 March 2023, excluding COVID-19 rapid antigen tests.
Diagnostics segment sales declined 39.0% on a comparable basis, again due to the decline in the COVID-19 rapid antigen test business.
Adjusted EBIT fell by 30% to E681 million, resulting in a lower adjusted EBIT margin of 12.7%. Net profit slumped 81% to E108m. Adjusted basic EPS was lower than the same period last year, at E0.43. Excluding rapid antigen tests and transformation costs, adjusted basic EPS increased by 11%.
Copyright (c) 2023 CercleFinance.com. All rights reserved.